DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

849

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Darusentan
DRUG: Guanfacine
DRUG: Darusentan Placebo

Sponsor

Gilead Sciences